trending Market Intelligence /marketintelligence/en/news-insights/trending/c5MpgfzbMboEEHS4qkwm2g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Roche completes $4.3B acquisition of gene therapy developer Spark Therapeutics

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Roche completes $4.3B acquisition of gene therapy developer Spark Therapeutics

Roche Holding AG has completed the $4.3 billion acquisition of gene therapy developer Spark Therapeutics Inc. after securing all required regulatory approvals.

The Switzerland-based pharmaceutical giant on Dec. 16 concluded a tender offer, which was started in March, to acquire all outstanding shares of Philadelphia-based Spark for $114.50 apiece. Roche also managed to secure approvals from regulators in the U.S. and U.K., after the tender offer had been extended several times in the past months to allow the agencies to look further into the deal.

Spark's shares will no longer trade on the Nasdaq Stock Market, and the company will become a wholly owned unit of Roche. The unit will continue to operate independently within the Roche Group, according to a Dec. 17 press release.

Roche initially offered to buy Spark in February, with closing originally expected in the second quarter.